IN2014DN09359A - - Google Patents
Info
- Publication number
- IN2014DN09359A IN2014DN09359A IN9359DEN2014A IN2014DN09359A IN 2014DN09359 A IN2014DN09359 A IN 2014DN09359A IN 9359DEN2014 A IN9359DEN2014 A IN 9359DEN2014A IN 2014DN09359 A IN2014DN09359 A IN 2014DN09359A
- Authority
- IN
- India
- Prior art keywords
- opioid
- methods
- well
- pharmaceutical composition
- phosphatidylcholine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261642837P | 2012-05-04 | 2012-05-04 | |
PCT/US2013/031078 WO2013165577A1 (en) | 2012-05-04 | 2013-03-13 | Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN09359A true IN2014DN09359A (es) | 2015-07-17 |
Family
ID=49514721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN9359DEN2014 IN2014DN09359A (es) | 2012-05-04 | 2013-03-13 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150190523A1 (es) |
EP (1) | EP2854537A4 (es) |
JP (1) | JP2015515982A (es) |
KR (1) | KR20150006877A (es) |
CN (1) | CN104470361A (es) |
AU (1) | AU2013257211A1 (es) |
BR (1) | BR112014027496A2 (es) |
CA (1) | CA2872400A1 (es) |
HK (1) | HK1207940A1 (es) |
IL (1) | IL235390A0 (es) |
IN (1) | IN2014DN09359A (es) |
MX (1) | MX2014013425A (es) |
WO (1) | WO2013165577A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3718404A1 (en) | 2014-10-17 | 2020-10-07 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progession |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7846478B2 (en) * | 2002-01-31 | 2010-12-07 | Henkel Ag & Co. Kgaa | Bioadhesive composition |
CN101432011A (zh) * | 2006-02-27 | 2009-05-13 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质系统的方法 |
US8911777B2 (en) * | 2007-04-04 | 2014-12-16 | Sigmoid Pharma Limited | Pharmaceutical composition of tacrolimus |
JP5985824B2 (ja) * | 2008-07-01 | 2016-09-06 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド受容体アンタゴニスト含有の粒子および使用方法 |
US20110190267A1 (en) * | 2010-01-05 | 2011-08-04 | Shire Pharmaceuticals, Inc. | Prodrugs of opioids and uses thereof |
US20120053130A1 (en) * | 2010-08-30 | 2012-03-01 | Bristol-Myers Squibb Company | Composition for enhancing absorption of a drug and method |
-
2013
- 2013-03-13 EP EP13785315.6A patent/EP2854537A4/en not_active Withdrawn
- 2013-03-13 IN IN9359DEN2014 patent/IN2014DN09359A/en unknown
- 2013-03-13 CN CN201380028597.4A patent/CN104470361A/zh active Pending
- 2013-03-13 CA CA2872400A patent/CA2872400A1/en not_active Abandoned
- 2013-03-13 JP JP2015510266A patent/JP2015515982A/ja not_active Withdrawn
- 2013-03-13 WO PCT/US2013/031078 patent/WO2013165577A1/en active Application Filing
- 2013-03-13 AU AU2013257211A patent/AU2013257211A1/en not_active Abandoned
- 2013-03-13 US US14/398,914 patent/US20150190523A1/en not_active Abandoned
- 2013-03-13 KR KR20147034096A patent/KR20150006877A/ko not_active Application Discontinuation
- 2013-03-13 MX MX2014013425A patent/MX2014013425A/es unknown
- 2013-03-13 BR BR112014027496A patent/BR112014027496A2/pt not_active IP Right Cessation
-
2014
- 2014-10-29 IL IL235390A patent/IL235390A0/en unknown
-
2015
- 2015-09-07 HK HK15108676.7A patent/HK1207940A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1207940A1 (en) | 2016-02-19 |
CN104470361A (zh) | 2015-03-25 |
WO2013165577A1 (en) | 2013-11-07 |
BR112014027496A2 (pt) | 2018-05-15 |
JP2015515982A (ja) | 2015-06-04 |
AU2013257211A1 (en) | 2014-11-27 |
IL235390A0 (en) | 2014-12-31 |
CA2872400A1 (en) | 2013-11-07 |
EP2854537A4 (en) | 2016-04-06 |
EP2854537A1 (en) | 2015-04-08 |
US20150190523A1 (en) | 2015-07-09 |
MX2014013425A (es) | 2015-08-14 |
KR20150006877A (ko) | 2015-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL233592B (en) | The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain | |
HK1210939A1 (en) | Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents | |
SG194469A1 (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
MX371344B (es) | Antagonistas de il-4r para usarse en el tratamiento o prevención de asma persistente y asma severa. | |
NZ748451A (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
EP2680899A4 (en) | Medicament delivery device for administration of opioid antagonists including formulations for naloxone | |
WO2012032209A3 (es) | Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora. | |
MX354125B (es) | Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. | |
MX366899B (es) | Nuevos compuestos. | |
MX348933B (es) | Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico. | |
DK201270677A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
MX2016004741A (es) | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. | |
EP2925340B8 (en) | Pharmaceutical compositions comprising selective agonists of melanocortin 1 receptor and their use in therapeutic methods | |
HK1203391A1 (en) | Administration of an antagonist of alpha 5 beta1 for anti- antiogenesis and cancer treatment 51 | |
MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
GB201210686D0 (en) | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level | |
HK1196943A1 (zh) | 作為用於治療酒精依賴和濫用的 受體拮抗劑的螺噻吩並吡喃-呱啶衍生物 | |
IN2014DN09359A (es) | ||
MX358211B (es) | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. | |
TR201803744T4 (tr) | Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler. | |
MX2019009243A (es) | Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa. | |
IN2013MU02852A (es) | ||
PH12014501390A1 (en) | Novel therapeutic use of p75 receptor antagonists | |
UA96048C2 (ru) | Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия |